by: Parent Project Muscular Dystrophy
Roche/Genentech recently joined Parent Project Muscular Dystrophy for a webinar to provide an update on their Anti-Myostatin Adnectin (RG6206) development program.
The team at Roche and its US affiliate, Genentech, and provided an overview of how they are collaborating with the Duchenne community, as well as an update on their Anti-Myostatin Adnectin (RG6206) program, including the status of ongoing clinical studies.
